OmniAb, Inc.
Alexandra Mulcahy started their work experience as a Co-op at Dyax, where they managed and transformed cell lines for antigen expression. Alexandra then worked as an HLA Assistant at the American Red Cross before becoming a Research Assistant at Merck. After that, they worked as a Laboratory Technician at Northeastern University. Alexandra then pursued a PhD at The University of Nottingham, focusing on pluripotency genes involved in the development of stem cells and germ cells. Following their PhD, they joined Agios Pharmaceuticals as a Biology Contractor for Rare Genetic Diseases, where they later became an Associate Scientist and a Senior Research Associate. At Agios, Alexandra explored neural stem-like cell cultures and contributed to the development of new pharmaceutical targets. In 2022, they joined Resilience as a Scientist I, where they implemented advanced technology and automation to characterize their iPSC generation platform. Currently, Alexandra works at OmniAb, Inc. as an Associate Scientist in Primordial Germ Cell Technology.
Alexandra Mulcahy has a diverse education history. Alexandra pursued a PhD in Biochemistry at the University of Nottingham from 2015 to 2017, focusing on Developmental Biology, Evolution, and Molecular Pathways. Prior to that, they completed their Master's degree in Biotechnology at Northeastern University between 2006 and 2013, with a specialization in Molecular Cellular Biotechnology. Alexandra also obtained a Bachelor of Science degree in Biochemistry from Northeastern University from 2006 to 2011.
In addition to their formal education, Alexandra has acquired additional certifications. Alexandra holds a FACS Aria Training Course Certification from BD Biosciences, obtained in March 2022. Alexandra also completed the Fundamentals of Cell Culture Training Course, offered by The European Collection of Authenticated Cell Cultures (ECACC); however, the specific month and year of completion are not provided.
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.